**Name of Journal: *World Journal of Hepatology***

**Manuscript NO: 36923**

**Manuscript Type: Minireviews**

**Metabolomics: From liver chiromancy to personalized precision medicine in advanced chronic liver disease**

Procopet B *et al*. Metabolomics in advanced chronic liver diseases

**Bogdan Procopet, Petra Fischer, Oana Farcau, Horia Stefanescu**

**Bogdan Procopet, Petra Fischer, Oana Farcau,** 3rd Medical Clinic, University of Medicine and Pharmacy, Cluj 400162, Romania

**Bogdan Procopet, Horia Stefanescu,** Hepatology Unit, Regional Institute of Gastroenterology and Hepatology, Cluj 400162, Romania

**ORCID number:** Bogdan Procopet (0000-0001-8118-1760); Petra Fischer (0000-0002-3605-8007); Oana Farcau (0000-0002-4468-2053); Horia Stefanescu (0000-0002-4034-5471).

**Author contributions:** Procopet B and Stefanescu H designed the study; Fischer P and Farcau O drafted the first version of the manuscript; all authors reviewed the manuscript and approved the final version of the paper.

**Supported by** Romanian Agency for Scientific Research, No. PN-II-RU-TE-2014-4-0356 (awarded to Stefanescu H) and No. PN-II-RU-TE-2014-4-0709 (awarded to Procopet B).

**Conflict-of-interest statement:** None.

**Open-Access:** This article is an open-access article which was selected byan in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/

**Manuscript source:** Invited manuscript

**Correspondence to: Horia Stefanescu, MSc, MD, PhD, Doctor, Staff Physician,** Hepatology Unit, Regional Institute of Gastroenterology and Hepatology, 19-21 Croitorilor str., Cluj 400162, Romania. horia.stefanescu@irgh.ro

**Telephone:** +4-0766-318283

**Received:** October 28, 2017

**Peer-review started:** October 29, 2017

**First decision:** November 28, 2017

**Revised:** January 19, 2018

**Accepted:** January 29, 2018

**Article in press:**

**Published online:**

**Abstract**

Currently there is a lack of accurate biomarkers for diagnosis and prognosis in advanced liver diseases. Either the occurrence of first decompensation, or diagnosis of acute on chronic liver failure, severe alcoholic hepatitis, or hepatocellular carcinoma (HCC), none of the available biomarkers are satisfactory. Metabolomics is the newest of omics, being much closer than the others to the actual phenotype and pathologic changes that characterizes a certain condition. It deals with a much wider spectrum of low molecular weight bio-compounds providing a powerful platform for discovering novel biomarkers and biochemical pathways to improve diagnostic, prognostication and therapy. Until now metabolomics was applied in a wide spectrum of liver conditions, but the findings were contradictory. This review proposes a synthesis of the existing evidences of metabolomics use in advanced chronic liver diseases, decompensated liver cirrhosis, severe alcoholic hepatitis and HCC.

**Key words:** Metabolomics; Biomarker; Prediction; Advanced chronic liver disease; Decompensation; Alcoholic hepatitis; Hepatocellular carcinoma

© **The Author(s) 2018**. Published by Baishideng Publishing Group Inc. All rights reserved.

**Core tip:** Currently there is a lack of accurate biomarkers for diagnosis and prognosis in advanced liver diseases. Either the occurrence of first decompensation, or diagnosis of acute on chronic liver failure, severe alcoholic hepatitis, or hepatocellular carcinoma (HCC), none of the available biomarkers are satisfactory. This review proposes a synthesis of the existing evidences of metabolomics use in advanced chronic liver diseases, decompensated liver cirrhosis, severe alcoholic hepatitis and HCC.

Procopet B, Fischer P, Farcau O, Stefanescu H. Metabolomics: From liver chiromancy to personalized precision medicine in advanced chronic liver disease. *World J Hepatol* 2018; In press

**INTRODUCTION**

Hepatic fibrosis is a dynamic process that may progress to liver cirrhosis in the context of an active etiological factor. In compensated stages, physical exam by itself cannot distinguish between severe fibrosis and constituted liver cirrhosis. This is why in recent years the term compensated advanced chronic liver disease (cACLD) was introduced[1]. In this stage it is essential to establish the risk of decompensation and the best method to do it is by measuring hepatic venous pressure gradient (HVPG)[2]. However, HVPG measurement is not widely available and it is considered invasive[3]. Therefore, in the last years huge efforts were done to find new biomarkers or non-invasive methods to assess prognosis.

The occurrence of decompensation, with its various manifestations (ascites and variceal bleeding most often) is in direct relation with the increase in portal pressure, namely clinically significant portal hypertension, which represent an HVPG > 10 mmHg[4]. The life expectancy of these patients without liver transplantation is significantly lower than in compensated stages[5].

Acute decompensation associated with organ failures and increased short-term mortality is defined by the concept of acute on chronic liver failure (ACLF) syndrome, which was recently defined[6]. The most frequent precipitating factors for ACLF are bacterial infections, acute flares in viral B advanced liver disease and alcohol consumption but the clinical features are identical regardless the precipitating factor[7]. There are some clinical situations where making a therapeutic decision based on the available non-invasive diagnostic tools proves to be difficult. Thus, without liver biopsy it is impossible to differentiate between severe alcoholic hepatitis and decompensated cirrhosis, which is essential for the indication of cortisone treatment[8]. Moreover, around one third of decompensated patients are infected at presentation[9,10] and without routine cultures the clinical suspicion and diagnosis of bacterial infections is very difficult. To reduce in hospital-morbidity and mortality, early initiation of empiric antibiotherapy can be crucial, but bacterial cultures last long, and infection markers represented by CRP, leucocyte count, procalcitonin are of limited value in cirrhosis[11]. Therefore, in these specific clinical scenarios new biomarkers for diagnosis and prognosis are also needed.

Apart from acute decompensation, the prognosis of patients with cACLD is deeply influenced by hepatocellular carcinoma (HCC) occurrence[12]. The high mortality rate of HCC is owed partly to the absence of adequate monitoring in high-risk populations, and partly to insufficient diagnostic resources - especially for early tumor identification, which could still allow curative interventions. Serum alpha-fetoprotein (AFP) - which has been widely and commonly used as biomarker, either as a screening tool for early HCC detection or as a prognostic tool for tumor recurrence and patient survival, has a poor sensitivity since up to 40% of HCC and cirrhosis patients have normal AFP levels and only 10%-20% of patients with early-stage HCC have elevated AFP levels[13]. Therefore, more sensitive markers of disease are needed, particularly for the early detection of HCC disease and for HCC recurrence after curative treatment.

Given the reserved prognosis and the difficulty of management, this review proposes a synthesis of the existing evidences of metabolomics use in cACLD, decompensated liver cirrhosis, severe alcoholic hepatitis and HCC.

**METABOLOMICS** **– NEW OPPORTUNITY FOR BIOMARKERS DISCOVERY**

Although its recognition as a distinct scientific area is much more recent than the other “omics” such as genomics, transcriptomics, or proteomics, metabolomics provides a powerful platform for discovering novel biomarkers and biochemical pathways to improve diagnostic, prognostication, and therapy (Figure 1)[14,15]. It has the advantage of being much closer to the actual phenotype than the other omics, but the number of possible compounds is much higher. In contrast to genomics, transcriptomics, and proteomics, which address macromolecules with similar chemical properties, such as DNA, RNA, and proteins, metabolomics deals with diverse properties of low molecular weight bio-compounds[16].

Metabolomics allows small metabolites, usually with a molecular weight under 1 kDa, and metabolic processes to be studied using nuclear magnetic resonance (NMR) spectroscopy, gas chromatography mass spectrometry (GC-MS), and liquid chromatography mass spectrometry (LC-MS)[17]. Given the nonvolatile character of biological materials (serum, urine, tissue or faeces) the most commonly used technique in clinical trials is LC-MS. The common pattern recognition methods of metabolomics include unsupervised and supervised ones: principal component analysis (PCA) for the former and partial least squares-discriminant analysis (PLS-DA) for the latter group.

**METABOLOMICS AND ADVANCED CHRONIC LIVER DISEASE**

Once the cACLD patients develop decompensation the progression of the disease is very clear. The annual transition rate from compensated to decompensated stage is the highest in HBV cirrhosis, around 10% per year, being lower in HCV and alcoholic etiologies[18,19]. However, without HVPG measurement, the most difficult task is to identify the patients at risk of decompensation or to accurately identify the precipitating factor.

It seems that with the progression of chronic liver diseases the core metabolic phenotype is characterized by a decrease in phosphatidylcholines (PC) and increase in serum biliary acids[20]. This core metabolic phenotype appears early in the natural history of chronic liver diseases, regardless the etiology, and remains stable in the evolution, including different stages of cirrhosis or hepatic tumors, either cholangio or hepatocellular carcinoma.

When comparing the metabolic profile of patients infected with HCV without fibrosis with HCV cirrhosis, along with this core metabolic phenotype, there are other several disorders involving lipid, carbohydrate, protein, and energetic metabolism[21]. The HDL cholesterol and choline levels were lower in patients with cirrhosis compared to those without fibrosis. The perturbations of glucose metabolism are caused, firstly, by impaired tricarboxylic acid cycle activity due to mitochondrial dysfunction, and possibly on the second hand by insulin resistance that characterizes HCV infection, leading to increased serum glucose and citrate levels in the cirrhotic group. As a response to the relative carbohydrate deficiency, ketone bodies (hydroxybutyrate and acetoacetate) are used as preferential energy sources in the mitochondria, explaining their lower serum levels with the evolution of hepatic disease.

Regarding protein metabolism, there is an imbalance in the ratio of aromatic amino acids and branched chain amino acids in cirrhosis. In fact, only phenylalanine was founded elevated in serum of patients with cirrhosis, probably because disturbances of the gut microbiota in this situation[22].

Jimenez *et al*[23] has attempted to identify by NMR spectroscopy the metabolic profile of cirrhotic patients with minimal hepatic encephalopathy (MHE) versus cirrhotic patients without encephalopathy. MHE patients displayed increased serum concentrations of glucose, lactate, methionine and glycerol, as well as decreased levels of choline, branched chain amino acids, alanine, glycine, acetoacetate, and lipid moieties.

When serum metabolic profile by NMR spectroscopy of patients in different stages of chronic liver failure (CLF) according to the MELD score was analyzed, there is an evolutionary trend involving the representatives of the metabolism of lipids, carbohydrates and proteins[24]. Thus, there is a decrease in HDL cholesterol, choline and phosphatidylcholine, which are the more expressed in higher MELD patients. The glucose, lactic acid, butyrate, pyruvate and citrate levels increase in severe CLF and the protein metabolism is modified because increased skeletal muscle catabolism, expressed by increased levels of free amino acids (leucine, isoleucine, glutamine, methionine and valine) in parallel with the severity of liver disease.

Recently, it was proved that phosphatidylcholine and lysophosphatidylcholine may have also prognosis relevance in decompensated liver cirrhosis, serum levels of these compounds being negatively correlated with survival[25].

Therefore, there is no single biomarker for the different stages of advanced chronic liver disease, but a complex of biomarkers, a so-called metabolic fingerprint. This implies, regardless of the etiology of liver disease, progressive changes of the same classes of compounds in parallel with disease evolution.

**METABOLOMICS AND ACUTE-ON-CHRONIC LIVER FAILURE**

ACLF is a distinct syndrome that can occur in approximately one third of patients with decompensated liver cirrhosis[6]. The most common causes are bacterial infections, alcohol consumption and digestive bleeding, although in a large percentage of cases a precipitating factor cannot be identified[7].

Amathieu *et al*[26] compared the metabolic profile of patients with ACLF with the one of patients with decompensated liver cirrhosis who do not meet the criteria for ACLF. The patients with ACLF had decreased HDL cholesterol, increased lactic acid, pyruvate, and aromatic amino acids but these changes are rather the expression of the severity of liver disease.

Because indirect infection markers have limited value in cirrhotic patients and bacteriological studies last long, identifying bacterial infections in a patient with decompensated liver cirrhosis or ACLF could be difficult. Although there is a strong need for new biomarkers in infection, there are no publications regarding the metabolic profile of the infected cirrhotic patients.

In severe sepsis and septic shock in non-cirrhotic patients it was identified a urinary metabolic profile with prognostic value, characterized by higher levels of ethanol, glucose, hippurate, but lower levels of methionine, glutamine, arginine and phenylalanine in patients with lower survival[27]. A retrospective multicenter study in Greece and Germany, which enrolled a large number of patients proposed as a primary endpoint to differentiate the metabolic profile of patients with SIRS from patients with sepsis and as a secondary endpoint, to identify specific biomarkers for the different types of infections[28]. A regression model combining the sphingolipid SM C22:3 and the glycerophospholipid lysoPCaC24:0 was created for sepsis diagnosis with a sensitivity of 84.1% and specificity of 85.7%. The glycerophospholipid lysoPCaC26:1 was characteristic for patients with community-acquired pneumonia complicated with severe sepsis or septic shock. For the other types of infection, no biomarker or significant metabolic profile was found.

For diagnosis of sepsis in emergency department, one study identified a panel of 6 metabolites, represented by myristic acid, citric acid, isoleucine, norleucine, pyruvic acid and a phosphocholine like derivative, to have very good sensitivity (95%) and specificity (90%)[29].

It is to be demonstrated if all these metabolic markers of infection may be applied in the context of decompensated cirrhosis or ACLF.

**METABOLOMICS AND ALCOHOLIC LIVER DISEASE**

Alcohol liver disease encompasses a spectrum of injury ranging from simple steatosis to frank cirrhosis and alcohol consumption may represent a precipitating factor for decompensation or ACLF[8]. Because most cases of alcoholic hepatitis occur in patients with established cirrhosis, most of the times it is impossible to differentiate between severe alcoholic hepatitis and decompensated cirrhosis without liver biopsy[8]. Accordingly, new biomarkers capable to differentiate between severe alcoholic hepatitis and decompensated cirrhosis as well as markers capable to predict early the response to corticosteroid therapy, would be of great help in clinical practice.

Urinary indole-3-acetic acid has been identified as a potential biomarker for early alcoholic liver disease on animal model, by two studies performed by LC-MS[30,31]. Our group, in a pilot study, proved that lyso-phosphatidylcholine16:1 and 20:4 decease progressively with the severity of alcoholic liver disease and this is correlated with survival and the occurrence of liver related events[32]. However, if these metabolic changes are rather general in ACLD or specific to alcoholic liver disease remains to be proved.

There are only few small studies in the literature regarding the metabolic profile of the patient with severe alcoholic hepatitis. Enhanced adipose tissue lipolysis with increased fatty acid supply to the liver is a phenomenon observed in severe alcoholic hepatitis[33]. In severe alcoholic hepatitis, there is an impaired long-chain fatty acid beta-oxidation in the liver, first because of the oversaturation of hepatic metabolic capacity due to excessive fatty acid supply and second because of impaired mitochondrial function. Eicosapentaenoate (EPA; 20:5n3) and docosapentaenoate (DPA;22:5n6), 2 long chain essential fatty acids, have been identified as potential biomarkers for severe alcoholic hepatitis by Rachakonda *et al*[33,34], capable to differentiate severe alcoholic hepatitis from compensated alcoholic liver cirrhosis.

As a consequence of faulty beta-oxidation, the same study demonstrated a relative transition to lipid omega-oxidation in severe alcoholic hepatitis, with the increase of dicarboxylic acids such as tetradecanedioate, hexadecanedioate, octadecanedioate, which are endogenous ligands of the peroxisome proliferator activated receptor (PPAR) alpha, mechanism at least partially responsible for the developing of severe steatosis in alcoholic hepatitis[34]. Severe alcoholic hepatitis is characterized by intrahepatic cholestasis. An increase in sulphated bile acids has been demonstrated in the serum of patients with severe alcoholic hepatitis, with a decrease in bile acids from intestinal bacterial origin, reflecting probably gut microbiota disturbances[34]. Carbohydrate metabolism is also impaired and implicates mainly the dysfunction of the Krebs cycle activity, with an increase in serum concentrations of the intermediates of the cycle, like fumarate, succinate, malate, citrate. Glucose is poorly used in severe alcoholic hepatitis, and there is a shunting from glycolysis to the pentose phosphor pathway, the end product of this, xylonate, being an important biomarker for severe alcoholic hepatitis.

Branched chain amino acids originating in skeletal muscles appear to be an important energy substitute in severe alcoholic hepatitis, as their serum levels (valine and isoleucine) are reduced in parallel with the increase of their metabolites[34].

Ascha *et al*[35] identified two compounds, betaine and citrulline, as important biomarkers for the differentiation of severe alcoholic hepatitis from decompensated liver cirrhosis. Betaine is a methylating agent involved in preserving the integrity of the hepatic cell, while citrulline has intestinal origin and appears to be elevated alongside NO, secondary to an excessive nitric oxyde synthaseactivity in the context of significant portal hypertension in alcoholic hepatitis[35].

**METABOLOMICS AND HCC**

Lysophosphatidylcholine (LPC) is an important signaling molecule, involved in regulating cellular proliferation, cancer cell invasion, and inflammation[36] and it has been reported to be significantly decreased in the sera of HCC patients[37,38]. In a recent study, lower levels of LPC and phosphatidylcholine (PC), such as LPC (16:0), LPC (18:0), PC (16:0), and PC (18:0) were observed in HCC and liver cirrhosis samples compared with healthy controls[37]. Low levels of LPCs imply an anti-inflammatory status in HCC patients, and markedly low levels of LPCs represent a severe immune suppression status in cirrhotic patients. Similar LPC trends have also been found in other malignant diseases, such as renal cell carcinoma[39].

Other serum lipid compounds found to be discriminative between HCC and healthy controls are Free Fatty Acids (FFA). Amongst them, oleamide (cis-9, 10-octadecenoamide), the amide of FFA C18:1 (oleic acid), may represent a specific marker for HCC[36,40]. Gao *et al*[41] reported a gradual up-regulation of the ratio of FFA C16:1 to C16:0 and FFA C18:1 to C18:0 during hepatocarcinogenesis as a result of significantly increased level of stearoyl-CoA desaturase 1(SCD1), due to the increased demand for lipid synthesis in HCC.

Bile acids are synthesized in the liver and aid in fatty acid absorption and digestion and constitutes one of the most frequently reported compound classes suggested as discriminating between HCC patients and a control group. Cholic acid, chenodeoxycholic acid, lithocholic acid and deoxycholic acid had lower levels in HCC patients compared with cirrhosis[40,42]. Also, glycochenodeoxycholic acid 3-sulfate (3-sulfo- GCDCA), glycocholic acid (GCA), glycodeoxycholic acid (GDCA), taurocholic acid (TCA), and taurochenodeoxycholate (TCDCA) are down regulated HCC *vs* cirrhosis[37,42]. Bile acid downregulation in HCC may also reflect a metabolic shift away from β-oxidation and the reduced de novo bile acid production caused by the obliteration of healthy hepatocytes during chronic liver disease[43].

As the liver is the major organ of protein metabolism it is not surprising that a dysregulation of amino acids was found in several studies specifically a decrease in branched chain amino acids (BCAAs: leucine, isoleucine, and valine) and an increase in aromatic amino acids (AAAs: phenylalanine, tryptophan, tyrosine, and histidine) in HCC patients *vs* healthy controls, indicating enhanced BCAA catabolism and reduced AAA breakdown in the failing liver[44,45]. BCAAs have been reported to have a crucial role in cancer by regulating the anabolic process involving protein synthesis and degradation. Alteration of these metabolic pathways was observed after RFA intervention, indicating that application of electrical current during RFA treatment causes burns in the liver and produces coagulative necrosis which results in parenchymal and tumor cell death, enhancement of consumption of BCAA, such as isoleucine which may characterize the inflammatory response in liver[46].

Baniasadi *et al*[47] used a targeted approach based on liquid chromatography resolved tandem mass spectrometry (LC-MS/MS) on 73 metabolites out of which 16 were statistically different between the serum of HCC *vs* cirrhotic HCV patients. Among them, 4 metabolites (methionine, 5-hydroxymethyl-2′-deoxyuridine, N2,N2- dimethylguanosine and uric acid) showed an excellent separation between the two group patients with a sensitivity of 97% and specificity of 95% and an AUROC of 0.98.

Prognostication for HCC after curative treatment is difficult, in part due to the lack of useful biomarkers that would allow for the selection of patients at higher risk of tumor recurrence or enable accurate assessment of treatment response.

Goossens *et al*[46] evaluated through 1H-NMR analysis, preoperatively and at various time points post-RFA, the metabolic profile of serum samples from HCC patients in order to identify factors associated with treatment response and recurrence in viral and non-viral HCC patients. The analysis was able to discriminate in the serum of viral HCC between t0 (pre-ablation) and t2 ( at 1 to 4 mo post ablation), the t2 being mainly characterized by an increase of glucose, glycerol, methylhistidine , and a decrease of lipids, 3-hydroxybutyrate, and choline but it was not able to predict HCC recurrence.

Zhou *et al*[48] evaluated early postoperative recurrence metabolic disturbances in HCC patients and demonstrated that bile acids, steroids and fatty acids showed significant variation in the early recurrent HCC group compared to the late recurrence group. Moreover, with the combination of methionine, GCDCA and cholesterol sulfate, 80% of the early recurrent HCCs can be predicted correctly with the corresponding AUROC equal to 0.91.

As previously shown there are no specific metabolic changes during the carcinogenetic process and, therefore, by now there is no specific marker to be proposed for diagnostic and prognostic of patients with HCC. Although metabolomics is a powerful strategy for identifying a large panel of metabolites that exhibit promise in accurately diagnosing HCC, integrating two or more “omics” approaches can unveil the complex genomic-proteomic-metabolic network galvanizing cancer development. With this regard, Beyoğlu et al performed a combined transcriptomics and metabolomics study and was able to evaluate the metabolic profile of G1 to G6 transcriptomics groups of HCC[49].

**CONCLUSION**

The main limitation to the generalization of the results of existing publication is that the methodology used by different groups is not uniform and, thus, the results are sometimes contradictory. Other possible explanation for this variability is the fact that the majority of the studies use non-targeted metabolic analysis and identification of different metabolites is based on molecular mass, which can be similar for different compounds. Despite the important progress that has been made in technology and in understanding the pathological processes, when talking about specific biomarkers for advanced chronic liver diseases we are still in an era of uncertainty and chiromancy.

However, what appears to be a fact, is that during the progression of liver diseases, regardless the etiology, there is a core represented by decrease in serum lysophosphatidylcholine and an increased in bile acids[20]. These changes augment with the progression of the disease and that’s explains the prognostic relevance of these changes. Besides that, several candidate metabolomic biomarkers have been identified in these clinical scenarios. They reflect the changes that occur mainly in lipids, amino-acids and energetic metabolism. Nevertheless, none of them was widely and independently validated, or have been translated into clinical practice.

It is our strong belief that the diversity and quality of emerging data would allow the selection of the best method for metabolomics and further studies would validate new biomarkers for those scenarios where clinical needs are still unmet. Probably, the solution would be to interdisciplinary analyze the data through system's biology, allowing the integration of clinical, biochemical, imaging and “omics” findings, so that we'll be moving towards the era of personalized precision medicine in advanced chronic liver diseases.

**REFERENCES**

1 **de Franchis R.** Expanding consensus in portal hypertension Report of the Baveno VI Consensus Workshop: Stratifying risk and individualizing care for portal hypertension. *J Hepatol [Internet].* *European Association for the Study of the Liver* 2015; **63:** 543-545 [DOI: 10.1016/j.jhep.2015.05.022]

2 **Ripoll C**, Groszmann R, Garcia-Tsao G, Grace N, Burroughs A, Planas R, Escorsell A, Garcia-Pagan JC, Makuch R, Patch D, Matloff DS, Bosch J; Portal Hypertension Collaborative Group. Hepatic venous pressure gradient predicts clinical decompensation in patients with compensated cirrhosis. *Gastroenterology* 2007; **133**: 481-488 [PMID: 17681169 DOI: 10.1053/j.gastro.2007.05.024]

3 **Procopeț B,** Tantau M, Bureau C. Are there any alternative methods to hepatic venous pressure gradient in portal hypertension assessment? *J Gastrointestin Liver Dis* 2013; **22:** 73-78 [PMID: 23539394]

4 **Berzigotti A**, Seijo S, Reverter E, Bosch J. Assessing portal hypertension in liver diseases. *Expert Rev Gastroenterol Hepatol* 2013; **7**: 141-155 [PMID: 23363263 DOI: 10.1586/egh.12.83]

5 **Ripoll C**, Bañares R, Rincón D, Catalina MV, Lo Iacono O, Salcedo M, Clemente G, Núñez O, Matilla A, Molinero LM. Influence of hepatic venous pressure gradient on the prediction of survival of patients with cirrhosis in the MELD Era. *Hepatology* 2005; **42**: 793-801 [PMID: 16175621 DOI: 10.1002/hep.20871]

6 **Moreau R**, Jalan R, Gines P, Pavesi M, Angeli P, Cordoba J, Durand F, Gustot T, Saliba F, Domenicali M, Gerbes A, Wendon J, Alessandria C, Laleman W, Zeuzem S, Trebicka J, Bernardi M, Arroyo V; CANONIC Study Investigators of the EASL–CLIF Consortium. Acute-on-chronic liver failure is a distinct syndrome that develops in patients with acute decompensation of cirrhosis. *Gastroenterology* 2013; **144**: 1426-1437, 1437.e1-1437.e9 [PMID: 23474284 DOI: 10.1053/j.gastro.2013.02.042]Available]

7 **Arroyo V**, Moreau R, Kamath PS, Jalan R, Ginès P, Nevens F, Fernández J, To U, García-Tsao G, Schnabl B. Acute-on-chronic liver failure in cirrhosis. *Nat Rev Dis Primers* 2016; **2**: 16041 [PMID: 27277335 DOI: 10.1038/nrdp.2016.41]

8 **European Association for the Study of Liver.** Management of Alcoholic Liver Disease. *J Hepatol* 2012; **57:** 399-420 [PMID: 22633836 DOI: 10.1016/j.jhep.2012.04.004]

9 **Fernandez J,** Acevedo J, Castro M, Garcia O, Rodriguez de Lope C, Roca D, Pavesi M, Sola E, Moreira L, Silva A, Seva-Pereira T, Corradi F, Mensa J, Gines P, Arroyo V. Prevalence and Risk Factors of Infections by Multiresistant Bacteria in Cirrhosis: A Prospective Study. *Hepatology* 2012; **55:** 1551-61 [PMID: 22183941 DOI: 10.1002/hep.25532]

10 **Fernández J**, Acevedo J, Wiest R, Gustot T, Amoros A, Deulofeu C, Reverter E, Martínez J, Saliba F, Jalan R, Welzel T, Pavesi M, Hernández-Tejero M, Ginès P, Arroyo V; European Foundation for the Study of Chronic Liver Failure. Bacterial and fungal infections in acute-on-chronic liver failure: prevalence, characteristics and impact on prognosis. *Gut* 2017 [PMID: 28847867 DOI: 10.1136/gutjnl-2017-314240]

11 **Alexopoulou A**, Agiasotelli D, Vasilieva LE, Dourakis SP. Bacterial translocation markers in liver cirrhosis. *Ann Gastroenterol* 2017; **30**: 486-497 [PMID: 28845103 DOI: 10.20524/aog.2017.0178]

12 **Cabibbo G**, Enea M, Attanasio M, Bruix J, Craxì A, Cammà C. A meta-analysis of survival rates of untreated patients in randomized clinical trials of hepatocellular carcinoma. *Hepatology* 2010; **51**: 1274-1283 [PMID: 20112254 DOI: 10.1002/hep.23485]

13 **Dufour JF,** Greten TF, Raymond E, Roskams T, De T, Ducreux M, Mazzaferro V, Governing E. Clinical Practice Guidelines EASL – EORTC Clinical Practice Guidelines: Management of hepatocellular carcinoma European Organisation for Research and Treatment of Cancer, 2012: 56

14 **Lindon JC**, Holmes E, Nicholson JK. Metabonomics in pharmaceutical R&amp;D. *FEBS J* 2007; **274**: 1140-1151 [PMID: 17298438 DOI: 10.1111/j.1742-4658.2007.05673.x]

15 **Wang X**, Zhang A, Sun H. Power of metabolomics in diagnosis and biomarker discovery of hepatocellular carcinoma. *Hepatology* 2013; **57**: 2072-2077 [PMID: 23150189 DOI: 10.1002/hep.26130]

16 **Yoshida M**, Hatano N, Nishiumi S, Irino Y, Izumi Y, Takenawa T, Azuma T. Diagnosis of gastroenterological diseases by metabolome analysis using gas chromatography-mass spectrometry. *J Gastroenterol* 2012; **47**: 9-20 [PMID: 22041921 DOI: 10.1007/s00535-011-0493-8]

17 **Patel NR,** McPhail MJ, Shariff MI, Keun HC, Taylor-Robinson SD. Biofluid metabonomics using 1 H NMR spectroscopy: the road to biomarker discovery in gastroenterology and hepatology. *Expert Rev Gastroenterol Hepatol* 2012; **6:** 239-51 [PMID: 22375528 DOI: 10.1586/egh.12.1]

18 **Schuppan D,** Afdhal NH. Liver cirrhosis. *Lancet* 2008; **371:** 838–51 [PMID: 18328931 DOI: 10.1016/S0140-6736(08)60383-9]

19 **Asrani SK**, Kamath PS. Natural history of cirrhosis. *Curr Gastroenterol Rep* 2013; **15**: 308 [PMID: 23314828 DOI: 10.1007/s11894-012-0308-y]

20 **Beyoğlu D**, Idle JR. The metabolomic window into hepatobiliary disease. *J Hepatol* 2013; **59**: 842-858 [PMID: 23714158 DOI: 10.1016/j.jhep.2013.05.030]

21 **Embade N**, Mariño Z, Diercks T, Cano A, Lens S, Cabrera D, Navasa M, Falcón-Pérez JM, Caballería J, Castro A, Bosch J, Mato JM, Millet O. Metabolic Characterization of Advanced Liver Fibrosis in HCV Patients as Studied by Serum 1H-NMR Spectroscopy. *PLoS One* 2016; **11**: e0155094 [PMID: 27158896 DOI: 10.1371/journal.pone.0155094]

22 **Vernocchi P**, Del Chierico F, Putignani L. Gut Microbiota Profiling: Metabolomics Based Approach to Unravel Compounds Affecting Human Health. *Front Microbiol* 2016; **7**: 1144 [PMID: 27507964 DOI: 10.3389/fmicb.2016.01144]

23 **Jiménez B,** Montoliu C, Macintyre D a, Serra M a, Wassel A, Romero-gomez M, Rodrigo JM, Pineda-lucena A, Felipo V. Serum metabolic signature of minimal hepatic encephalopathy by (1)H-nuclear magnetic resonance. *J Proteome Res* 2010; **9:** 5180-5187 [PMID: 20690770 DOI: 10.1021/pr100486e]

24 **Amathieu R**, Nahon P, Triba M, Bouchemal N, Trinchet JC, Beaugrand M, Dhonneur G, Le Moyec L. Metabolomic approach by 1H NMR spectroscopy of serum for the assessment of chronic liver failure in patients with cirrhosis. *J Proteome Res* 2011; **10**: 3239-3245 [PMID: 21568267 DOI: 10.1021/pr200265z]

25 **McPhail MJW**, Shawcross DL, Lewis MR, Coltart I, Want EJ, Antoniades CG, Veselkov K, Triantafyllou E, Patel V, Pop O, Gomez-Romero M, Kyriakides M, Zia R, Abeles RD, Crossey MME, Jassem W, O'Grady J, Heaton N, Auzinger G, Bernal W, Quaglia A, Coen M, Nicholson JK, Wendon JA, Holmes E, Taylor-Robinson SD. Multivariate metabotyping of plasma predicts survival in patients with decompensated cirrhosis. *J Hepatol* 2016; **64**: 1058-1067 [PMID: 26795831 DOI: 10.1016/j.jhep.2016.01.003]

26 **Amathieu R**, Triba MN, Nahon P, Bouchemal N, Kamoun W, Haouache H, Trinchet JC, Savarin P, Le Moyec L, Dhonneur G. Serum 1H-NMR metabolomic fingerprints of acute-on-chronic liver failure in intensive care unit patients with alcoholic cirrhosis. *PLoS One* 2014; **9**: e89230 [PMID: 24586615 DOI: 10.1371/journal.pone.0089230]

27 **Garcia-Simon M**, Morales JM, Modesto-Alapont V, Gonzalez-Marrachelli V, Vento-Rehues R, Jorda-Miñana A, Blanquer-Olivas J, Monleon D. Prognosis Biomarkers of Severe Sepsis and Septic Shock by 1H NMR Urine Metabolomics in the Intensive Care Unit. *PLoS One* 2015; **10**: e0140993 [PMID: 26565633 DOI: 10.1371/journal.pone.0140993]

28 **Neugebauer S**, Giamarellos-Bourboulis EJ, Pelekanou A, Marioli A, Baziaka F, Tsangaris I, Bauer M, Kiehntopf M. Metabolite Profiles in Sepsis: Developing Prognostic Tools Based on the Type of Infection. *Crit Care Med* 2016; **44**: 1649-1662 [PMID: 27097292 DOI: 10.1097/CCM.0000000000001740]

29 **Kauppi AM**, Edin A, Ziegler I, Mölling P, Sjöstedt A, Gylfe Å, Strålin K, Johansson A. Metabolites in Blood for Prediction of Bacteremic Sepsis in the Emergency Room. *PLoS One* 2016; **11**: e0147670 [PMID: 26800189 DOI: 10.1371/journal.pone.0147670]

30 **Manna SK**, Patterson AD, Yang Q, Krausz KW, Idle JR, Fornace AJ, Gonzalez FJ. UPLC-MS-based urine metabolomics reveals indole-3-lactic acid and phenyllactic acid as conserved biomarkers for alcohol-induced liver disease in the Ppara-null mouse model. *J Proteome Res* 2011; **10**: 4120-4133 [PMID: 21749142 DOI: 10.1021/pr200310s]

31 **Manna S,** Thompson M, Gonzalez F. Application of mass spectrometry-based metabolomics in identification of early noninvasive biomarkers of alcohol-induced liver disease using mouse model. *Adv Exp Med Biol* 2015; 217-38 [PMID: 25427910 DOI: 10.1007/978-3-319-09614-8\_13]

32 **Stefanescu H,** Suciu A, Romanciuc F, Crisan D, Procopet B, Radu C, Tantau M, Socaciu C, Grigorescu M. Lyso-phosphatidylcholine: A potential metabolomic biomarker for alcoholic liver disease? *Hepatology* 2016; **64:** 678-9 [PMID: 27123871 DOI: 10.1002/hep.28630]

33 **Rachakonda V**, Gabbert C, Raina A, Li H, Malik S, DeLany JP, Behari J. Stratification of risk of death in severe acute alcoholic hepatitis using a panel of adipokines and cytokines. *Alcohol Clin Exp Res* 2014; **38**: 2712-2721 [PMID: 25421508 DOI: 10.1111/acer.12558]

34 **Rachakonda V**, Gabbert C, Raina A, Bell LN, Cooper S, Malik S, Behari J. Serum metabolomic profiling in acute alcoholic hepatitis identifies multiple dysregulated pathways. *PLoS One* 2014; **9**: e113860 [PMID: 25461442 DOI: 10.1371/journal.pone.0113860]

35 **Ascha M**, Wang Z, Ascha MS, Dweik R, Zein NN, Grove D, Brown JM, Marshall S, Lopez R, Hanouneh IA. Metabolomics studies identify novel diagnostic and prognostic indicators in patients with alcoholic hepatitis. *World J Hepatol* 2016; **8**: 499-508 [PMID: 27057307 DOI: 10.4254/wjh.v8.i10.499]

36 **Kimhofer T**, Fye H, Taylor-Robinson S, Thursz M, Holmes E. Proteomic and metabonomic biomarkers for hepatocellular carcinoma: a comprehensive review. *Br J Cancer* 2015; **112**: 1141-1156 [PMID: 25826224 DOI: 10.1038/bjc.2015.38]

37 **Wang B,** Chen D, Chen Y, Hu Z, Cao M, Xie Q, Chen Y, Xu J, Zheng S, Li L. Metabonomic Profiles Discriminate Hepatocellular Carcinoma from Liver Cirrhosis by Ultraperformance Liquid Chromatography? Mass Spectrometry. *J Proteome Res* 2012; **11:** 1217-1227 [PMID: 22200553 DOI: 10.1021/pr2009252]

38 **Liu Y**, Hong Z, Tan G, Dong X, Yang G, Zhao L, Chen X, Zhu Z, Lou Z, Qian B, Zhang G, Chai Y. NMR and LC/MS-based global metabolomics to identify serum biomarkers differentiating hepatocellular carcinoma from liver cirrhosis. *Int J Cancer* 2014; **135**: 658-668 [PMID: 24382646 DOI: 10.1002/ijc.28706]

39 **Lin L**, Huang Z, Gao Y, Yan X, Xing J, Hang W. LC-MS based serum metabonomic analysis for renal cell carcinoma diagnosis, staging, and biomarker discovery. *J Proteome Res* 2011; **10**: 1396-1405 [PMID: 21186845 DOI: 10.1021/pr101161u]

40 **Chen T**, Xie G, Wang X, Fan J, Qiu Y, Zheng X, Qi X, Cao Y, Su M, Wang X, Xu LX, Yen Y, Liu P, Jia W. Serum and urine metabolite profiling reveals potential biomarkers of human hepatocellular carcinoma. *Mol Cell Proteomics* 2011; **10**: M110.004945 [PMID: 21518826 DOI: 10.1074/mcp.M110.004945]

41 **Gao R**, Cheng J, Fan C, Shi X, Cao Y, Sun B, Ding H, Hu C, Dong F, Yan X. Serum Metabolomics to Identify the Liver Disease-Specific Biomarkers for the Progression of Hepatitis to Hepatocellular Carcinoma. *Sci Rep* 2015; **5**: 18175 [PMID: 26658617 DOI: 10.1038/srep18175]

42 **Ressom HW**, Xiao JF, Tuli L, Varghese RS, Zhou B, Tsai TH, Ranjbar MR, Zhao Y, Wang J, Di Poto C, Cheema AK, Tadesse MG, Goldman R, Shetty K. Utilization of metabolomics to identify serum biomarkers for hepatocellular carcinoma in patients with liver cirrhosis. *Anal Chim Acta* 2012; **743**: 90-100 [PMID: 22882828 DOI: 10.1016/j.aca.2012.07.013]

43 **Fitian AI**, Cabrera R. Disease monitoring of hepatocellular carcinoma through metabolomics. *World J Hepatol* 2017; **9**: 1-17 [PMID: 28105254 DOI: 10.4254/wjh.v9.i1.1]

44 **Chen S**, Kong H, Lu X, Li Y, Yin P, Zeng Z, Xu G. Pseudotargeted metabolomics method and its application in serum biomarker discovery for hepatocellular carcinoma based on ultra high-performance liquid chromatography/triple quadrupole mass spectrometry. *Anal Chem* 2013; **85**: 8326-8333 [PMID: 23889541 DOI: 10.1021/ac4016787]

45 **Fages A**, Duarte-Salles T, Stepien M, Ferrari P, Fedirko V, Pontoizeau C, Trichopoulou A, Aleksandrova K, Tjønneland A, Olsen A, Clavel-Chapelon F, Boutron-Ruault MC, Severi G, Kaaks R, Kuhn T, Floegel A, Boeing H, Lagiou P, Bamia C, Trichopoulos D, Palli D, Pala V, Panico S, Tumino R, Vineis P, Bueno-de-Mesquita HB, Peeters PH, Weiderpass E, Agudo A, Molina-Montes E, Huerta JM, Ardanaz E, Dorronsoro M, Sjöberg K, Ohlsson B, Khaw KT, Wareham N, Travis RC, Schmidt JA, Cross A, Gunter M, Riboli E, Scalbert A, Romieu I, Elena-Herrmann B, Jenab M. Metabolomic profiles of hepatocellular carcinoma in a European prospective cohort. *BMC Med* 2015; **13**: 242 [PMID: 26399231 DOI: 10.1186/s12916-015-0462-9]

46 **Goossens C**, Nahon P, Le Moyec L, Triba MN, Bouchemal N, Amathieu R, Ganne-Carrié N, Ziol M, Trinchet JC, Sellier N, Diallo A, Seror O, Savarin P. Sequential Serum Metabolomic Profiling after Radiofrequency Ablation of Hepatocellular Carcinoma Reveals Different Response Patterns According to Etiology. *J Proteome Res* 2016; **15**: 1446-1454 [PMID: 27015127 DOI: 10.1021/acs.jproteome.5b01032]

47 **Baniasadi H**, Gowda GA, Gu H, Zeng A, Zhuang S, Skill N, Maluccio M, Raftery D. Targeted metabolic profiling of hepatocellular carcinoma and hepatitis C using LC-MS/MS. *Electrophoresis* 2013; **34**: 2910-2917 [PMID: 23856972 DOI: 10.1002/elps.201300029]

48 **Zhou L**, Liao Y, Yin P, Zeng Z, Li J, Lu X, Zheng L, Xu G. Metabolic profiling study of early and late recurrence of hepatocellular carcinoma based on liquid chromatography-mass spectrometry. *J Chromatogr B Analyt Technol Biomed Life Sci* 2014; **966**: 163-170 [PMID: 24582150 DOI: 10.1016/j.jchromb.2014.01.057]

49 **Beyoğlu D**, Imbeaud S, Maurhofer O, Bioulac-Sage P, Zucman-Rossi J, Dufour JF, Idle JR. Tissue metabolomics of hepatocellular carcinoma: tumor energy metabolism and the role of transcriptomic classification. *Hepatology* 2013; **58**: 229-238 [PMID: 23463346 DOI: 10.1002/hep.26350]

**P- Reviewer:** [Puoti](https://www.f6publishing.com/Forms/Manuscript/Editorial/CurrentReviewers.aspx?id=36923) C, [Zheng](https://www.f6publishing.com/Forms/Manuscript/Editorial/CurrentReviewers.aspx?id=36923) YB, [Zhu](https://www.f6publishing.com/Forms/Manuscript/Editorial/CurrentReviewers.aspx?id=36923) HF **S- Editor:** Song XX **L- Editor:** **E- Editor:**

**Specialty type:** Gastroenterology and hepatology

**Country of origin:** Romania

**Peer-review report classification**

Grade A (Excellent): 0

Grade B (Very good): B

Grade C (Good): C


Grade D (Fair): 0

Grade E (Poor): E

**Table 1 Principal metabolic changes in advanced liver diseases**

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| **Condition** |  | | | | | |
| **Lipids** | **Bile acids** | **Carbo-hydrates** | **Energy and oxidative stress** | **Proteins and**  **Aminoacids** |
| ACLD | ↓ HDL Cholesterol  ↓ choline  ↓ phosphatidylcholine  ↓ lipid moieties |  | ↑ glucose  ↑ glycerol | ↓ OH-butyrate  ↓ aceto-acetate  ↑ lactate  ↑ pyruvate  ↑ citrate | ↑ Phe  ↓ Gli, Ala  ↓ branched AA  ↑ Leu, Iso-Leu, Val, Glu  ↑ methionine |
| ACLF | ↓ HDL cholesterol |  |  | ↑ lactate  ↑ pyruvate | ↑ aromatic AA |
| ALD | ↓ lyso-phosphatidilcholine  ↑ eico/doco -sapentaenoate  ↑ tetra/hexa/octa -decanedioate | ↑ sulphated bile acids | ↑ fumarate, succinate, malate, citrate  ↑ xylonate | ↑ indole 3-acetic acid (u)  ↑ betaine  ↑ citruline | ↓ Val, Iso-Leu |
| HCC | ↓ lysophosphatidilcholine  ↑ oleamide  ↑ stearoyl-CoA desaturase  ↓ 3-hydroxybutyrate  ↓ choline | ↓ (lito)cholic, (cheno)deoxy-cholic acids  ↓ GCA, GDCA, GCDCA, TCA, TCDCA | ↑ glucose, glycerol | ↓ OH-butyrate  ↓ xantine  ↑ canavanino succinate | ↓ BCAAs: Leu, Iso-Leu and Val  ↑ AAAs: Phe, Trp, Tyr, His  ↑ methionine, hydroxy-methyldeoxyuridine, dimethyl-guanosine, uric acid  ↑ methylhistidine |

ACLF: Acute on chronic liver failure; ACLD: Advanced chronic liver disease; ALD: Alcoholic liver disease; HCC: Hepatocellular carcinoma; AA: Aminoacids; AAA: Aromatic AA; BCAA: Branched chain AA; Ala: Alanine; Arg: Arginine; Gli: Glicine; Glu: Glutamate; His: Histidine; Phe: Phenylalanine; Leu: Leucine; Val: Valine; Trp: Triptofan; Tyr: Tyrosine; CA: Cholic acid; GCA: Glyco CA; GDCA: Glycodeoxy CA; GCDCA: Glycochenodeoxy CA; TCA: Tauro CA; TCDA: Tauro cheno deoxi CA; u: Urinary.



**Figure 1 Integration of metabolites into the "omics" pathway and basic principles of Metabolomics.**